In one paragraphArticle in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
24 authors.
My K HaCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-6262-341X Anna PostovskayaAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-0838-0728 Maria KuznetsovaCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-9834-9328 Pieter MeysmanAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-5903-633X Vincent Van DeurenAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-7734-5547 Sabrina Van IersselDepartment of General Internal Medicine, Infectious Disease and Tropical Medicine, Antwerp University Hospital, Edegem, Belgium.ORCID 0000-0003-2955-4130 Hans De ReuLaboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0003-0120-3160 Jolien SchippersCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
Karin PeetersCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
Hajar BesbassiCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
Leo HeyndrickxVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-5862-7821 Betty WillemsVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Joachim MariënDepartment of Ecology and Evolutionary Biology, University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-7023-445X Esther BartholomeusAntwerp Center for Translational Immunology and Virology (ACTIV), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0003-2127-5161 Koen VercauterenClinical Virology Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0003-1472-9938 Philippe BeutelsCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0001-5034-3595 Pierre Van DammeAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-8642-1249 Eva LionAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-2420-0301 Erika VliegheDepartment of General Internal Medicine, Infectious Disease and Tropical Medicine, Antwerp University Hospital, Edegem, Belgium.ORCID 0000-0002-4865-3030 Kris LaukensAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-8217-2564 Samuel CoenenLaboratory of Medical Microbiology (LMM), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-1238-8052 Kevin K AriënVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Benson OgunjimiCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-0831-2063 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
To complement serology as a tool in public health interventions, we introduced the "celluloepidemiology" paradigm where we leveraged pathogen-specific T cell responses at a population level to advance our epidemiological understanding of infectious diseases, using SARS-CoV-2 as a model. Applying flow cytometry and machine learning on data from more than 500 individuals, we showed that the number of T cells with positive expression of functional markers not only could distinguish patients who recovered from COVID-19 from controls and pre-COVID donors but also identify previously unrecognized asymptomatic patients from mild, moderate, and severe recovered patients. The celluloepidemiology approach was uniquely capable to differentiate health care worker groups with different SARS-CoV-2 exposures from each other. T cell receptor (TCR) profiling strengthened our analysis by revealing that SARS-CoV-2-specific TCRs were more abundant in patients than in controls. We believe that adding data on T cell reactivity will complement serology and augment the value of infection morbidity modeling for populations.
Indexed as
Communicable DiseasesCOVID-19SARS-CoV-2Flow CytometryHumansMachine LearningReceptors, Antigen, T-CellT-LymphocytesReceptors, Antigen, T-Cell
Identifiers
PMID40378227
PMCPMC12083542
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390